[BIIB] Biogen Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 287.53 Change: 4.46 (1.58%)
Ext. hours: 292.98 Change: 5.45 (1.9%)

chart BIIB

Refresh chart

Strongest Trends Summary For BIIB

BIIB is in the long-term up 180% above S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn?s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical tri

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS17.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.19% Sales Growth - Q/Q1.44% P/E14.2
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA20.83% ROE27.76% ROI24.82%
Current Ratio2.2 Quick Ratio1.86 Long Term Debt/Equity0.19 Debt Ratio0.2
Gross Margin88.36% Operating Margin45.28% Net Profit Margin33.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities77.22 M Cash From Investing Activities-1.76 B Cash From Operating Activities1.78 B Gross Profit2.31 B
Net Profit927.28 M Operating Profit1.23 B Total Assets16.76 B Total Current Assets5.62 B
Total Current Liabilities2.56 B Total Debt579.47 M Total Liabilities4.19 B Total Revenue2.59 B
Technical Data
High 52 week367.91 Low 52 week257.52 Last close358.11 Last change-0.11%
RSI84.19 Average true range11.63 Beta1.03 Volume1.07 M
Simple moving average 20 days10.98% Simple moving average 50 days17.89% Simple moving average 200 days16.97%
Performance Data
Performance Week3.01% Performance Month22.62% Performance Quart34.62% Performance Half3.97%
Performance Year27.01% Performance Year-to-date12.41% Volatility daily3.95% Volatility weekly8.83%
Volatility monthly18.1% Volatility yearly62.72% Relative Volume178.46% Average Volume1.85 M
New High New Low

News

2019-06-14 12:03:32 | Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

2019-06-13 17:50:09 | Biogen BIIB Gains But Lags Market: What You Should Know

2019-06-13 16:12:00 | Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s

2019-06-12 12:49:48 | Biogen Inc. NASDAQ:BIIB Insiders Increased Their Holdings

2019-06-12 09:27:01 | Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

2019-06-11 19:05:00 | Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019

2019-06-11 11:26:38 | Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

2019-06-10 16:40:26 | Is Biogen Inc. BIIB A Good Stock To Buy?

2019-06-10 08:08:05 | See what the IHS Markit Score report has to say about Biogen Inc.

2019-06-07 17:50:09 | Biogen BIIB Outpaces Stock Market Gains: What You Should Know

2019-06-07 17:00:09 | Celgene's Filing for Ozanimod Accepted for Review in US/EU

2019-06-07 05:41:57 | Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

2019-06-06 16:19:44 | Will This Downbeat Biotech Regain Investor Trust With ALS Drugs?

2019-06-06 10:38:00 | Biogen Stock Is Slipping Because Investors Don’t Buy Its News on Lou Gehrig’s Disease

2019-05-31 09:07:01 | Biogen Reports Interim Phase III Data on Diroximel Fumarate

2019-05-31 09:01:13 | What Are Gilead Sciences’ Key Growth Drivers in 2019?

2019-05-31 08:11:12 | Roche RHHBY Up 6.3% YTD on Strong Demand for New Drugs

2019-05-31 07:32:27 | How Is Biogen’s Tecfidera Positioned in 2019?

2019-05-31 07:32:18 | How Is Gilead Sciences Revamping Its NASH Strategy in 2019?

2019-05-30 18:00:12 | How Is Biogen’s Alzheimers’ Disease Pipeline Positioned in 2019?

2019-05-30 11:02:03 | PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts

2019-05-30 07:30:00 | New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

2019-05-30 07:15:00 | The Case for a Biogen Acquisition — and 3 Potential Targets

2019-05-29 17:50:09 | Biogen BIIB Dips More Than Broader Markets: What You Should Know

2019-05-29 08:59:12 | Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma

2019-05-28 07:00:00 | Primecap’s Golden Lineup: Its Six Funds Come in Pairs

2019-05-27 06:48:10 | Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems

2019-05-24 19:39:48 | For Anderson family, an early bet on SMA gene therapy

2019-05-24 19:39:48 | Novartis $2 million gene therapy for rare disorder is world's most expensive drug

2019-05-24 17:05:29 | Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?

2019-05-24 13:30:35 | Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

2019-05-24 10:55:55 | Biogen Stock One of the Best to Own Next Week

2019-05-24 09:31:01 | Biogen BIIB Down 0.3% Since Last Earnings Report: Can It Rebound?

2019-05-23 17:27:24 | Preclinical biotech Stoke Therapeutics plans $86M IPO

2019-05-23 15:53:07 | Earnings Preview: Veeva VEEV, Palo Alto Networks PANW, Workday WDAY

2019-05-23 09:17:01 | The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific

2019-05-23 09:06:00 | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

2019-05-23 07:10:24 | The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks

2019-05-22 16:30:08 | 3 Tech Stocks for Growth Investors to Buy Right Now

2019-05-22 14:43:06 | Top Research Reports for Chubb, Las Vegas Sands & Biogen

2019-05-22 11:34:03 | Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

2019-05-22 11:08:27 | Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1

2019-05-21 17:56:00 | The Best and Worst Big Biotech Stocks, According to One Analyst

2019-05-21 16:55:19 | We don't yet have the technology to cure Alzheimer's, health-care investor says

2019-05-21 15:00:33 | Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending

2019-05-20 16:30:57 | Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer

2019-05-20 07:40:00 | Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital

2019-05-20 07:30:00 | Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

2019-05-17 17:17:09 | Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

2019-05-16 14:54:49 | Wayfair cracks Fortune 500 list, joins 15 other Mass. companies